2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2652

Abnormal Expression of Long Noncoding RNA Lncrna-CMPK2 Facilitates Neutrophils Interferon Production By TLR7/8 Agonist Stimulation in SLE
Abstract Number: 1731

Abnormal Responses of γδ T Cell Subsets to Stimulation with Cardiolipin and Zoledronate in Systemic Sclerosis
Abstract Number: 680

Abnormalities in Complement System Are Related to Disease Severity in Systemic Lupus Erythematosus (SLE)
Abstract Number: 14

Abnormalities in Th1, Th2 and Th17 Lymphoid Subpopulations in Long-Term Evolution Primary Antiphospholipid Syndrome
Abstract Number: 462

ABP 710: Matching Critical Biological Functions with Infliximab
Abstract Number: 57

Accelerated Development of Aging-Associated and Instability-Induced Osteoarthritis in 12/15-Lipoxygenase Deficient Mice
Abstract Number: 1719

Accelerated Wound Healing in Megakaryocyte/Platelet-Specific Fli1 Knockout Mice Due to the up-Regulated Expression of Interferon-γ
Abstract Number: 340

Accessing Positive (but Not Negative) Online Reviews Is Associated with Increased Willingness to Take Medication
Abstract Number: 996

Accuracy of Canadian Administrative Health Data in Identifying Patients with Psoriasis and Psoriatic Arthritis Using Primary Care Medical Records As the Reference Standard
Abstract Number: 799

Acetylcholinesterase Is Highly Expressed in the Inflamed Vessel Wall of Patients with Giant Cell Arteritis
Abstract Number: 1630

Achievement of Lupus Low Disease Activity State (LLDAS) in the Early Phase of Systemic Lupus Erythematosus Prevent Damage Accrual
Abstract Number: 2549

Achievement of Minimal Disease Activity Is Associated with Improvements in Health-Related Quality of Life and Productivity in Psoriatic Arthritis Patients
Abstract Number: 2954

Achieving Balance and Diversity in Patient Engagement in Research: Perspectives from Patients
Abstract Number: 970

ACPA Activate Challenged Synovial Fibroblasts through a PAD Dependent Mechanism: A Potential Explanation of the “Second Hit Model” in RA
Abstract Number: 432

ACPA and RF As Predictors of Sustained Clinical Remission in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Cohort

« Previous Page
1
…
7
8
9
10
11
…
201
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].